# A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France

> **NCT04550247** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 362 (actual)

## Conditions studied

- Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04550247
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-02
- **Primary completion:** 2027-03-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550247, "A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04550247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*